AU2930797A - Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them - Google Patents

Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
AU2930797A
AU2930797A AU29307/97A AU2930797A AU2930797A AU 2930797 A AU2930797 A AU 2930797A AU 29307/97 A AU29307/97 A AU 29307/97A AU 2930797 A AU2930797 A AU 2930797A AU 2930797 A AU2930797 A AU 2930797A
Authority
AU
Australia
Prior art keywords
hypolipidaemic
preparation
pharmaceutical compositions
compositions containing
antidiabetic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29307/97A
Other languages
English (en)
Inventor
Sekar Reddy Alla
Ranjan Chakrabarti
Braj Bhushan Lohray
Vidya Bhushan Lohray
Rajagopalan Ramanujam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Research Foundation
Reddy Cheminor Inc
Original Assignee
Dr Reddys Research Foundation
Reddy Cheminor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Research Foundation, Reddy Cheminor Inc filed Critical Dr Reddys Research Foundation
Publication of AU2930797A publication Critical patent/AU2930797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU29307/97A 1997-05-02 1997-05-02 Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them Abandoned AU2930797A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/007417 WO1997041119A1 (en) 1997-05-02 1997-05-02 Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU2930797A true AU2930797A (en) 1997-11-19

Family

ID=22260829

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29307/97A Abandoned AU2930797A (en) 1997-05-02 1997-05-02 Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

Country Status (5)

Country Link
EP (1) EP0981526B1 (https=)
JP (1) JP2001518069A (https=)
AU (1) AU2930797A (https=)
DE (1) DE69727837T2 (https=)
WO (1) WO1997041119A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JP2003525908A (ja) 2000-03-08 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 血清脂質の低下
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
ATE348097T1 (de) 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
WO2003099818A1 (en) 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
JP2007501861A (ja) 2003-05-23 2007-02-01 カイロン コーポレイション Mc4−rアゴニストとしてのグアニジノ置換キナゾリノン化合物
BRPI0410654A (pt) * 2003-06-12 2006-06-20 Novo Nordisk As composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
WO2005051391A1 (en) 2003-11-19 2005-06-09 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー/エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ ノルディスク アクティーゼルスカブ Glp−1アゴニストを用いた薬剤誘発性肥満の中和
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
CN101137631A (zh) 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
RU2499795C2 (ru) 2005-07-04 2013-11-27 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
MX2008011123A (es) 2006-03-28 2008-09-30 High Point Pharmaceuticals Llc Benzotiazoles que tienen actividad de receptor h3 de histamina.
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
ES2377322T3 (es) 2006-11-15 2012-03-26 High Point Pharmaceuticals, Llc Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes
US7915299B2 (en) 2006-11-15 2011-03-29 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US20100055071A1 (en) * 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
JP2014510739A (ja) 2011-03-28 2014-05-01 ノヴォ ノルディスク アー/エス 新規のグルカゴン類似体
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
JP2020514365A (ja) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー/エス メラノコルチン4受容体に結合可能な二環式化合物
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
CA3219597A1 (en) * 2021-06-23 2022-12-29 F. Hoffmann-La Roche Ag Novel process
CN116217511B (zh) * 2023-03-22 2024-04-19 沈阳药科大学 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2826379B2 (ja) * 1990-01-22 1998-11-18 三共株式会社 チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW245716B (https=) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
IL113084A (en) * 1994-03-23 1999-01-26 Sankyo Co Thiazolidine and oxazolidine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EP0981526A1 (en) 2000-03-01
EP0981526B1 (en) 2004-02-25
JP2001518069A (ja) 2001-10-09
WO1997041119A1 (en) 1997-11-06
DE69727837T2 (de) 2004-12-30
DE69727837D1 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
AU2930797A (en) Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU2995497A (en) Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
HUP0003844A3 (en) Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
AU4821096A (en) Benzazepine-, benzoxazepine- and benzothiazepine-N-acetic derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
AU6362796A (en) Substituted 4-phenylaminothiazoles, their process for preparation and the pharmaceutical compositions containing them
AU2094397A (en) New arylglycinamide derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
ZA973850B (en) Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
AU2841199A (en) Novel bis-benzamide derivatives, method for making same pharmaceutical compositions containing them and use thereof as medicine
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
HU9701660D0 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, find pharmaceutical compositions containing them
ZA973848B (en) Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
AU6551198A (en) Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
AU8031598A (en) 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
AU6058496A (en) New aminophenylphosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them
HUP0003766A2 (en) Isoguinolin derivatives, process for producing them and pharmaceutical compositions containing them
HUP0003997A3 (en) 3-benzylpiperidine derivatives, pharmaceutical compositions containing them and process for producing them
AU5525199A (en) N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them
HUP0000952A3 (en) Carbapenem compounds, process for their preparation and pharmaceutical compositions containing them
HUP0001183A3 (en) Pyrrolothiazine and pyrrolothiazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0104202A3 (en) Thiazole-derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase